Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US Veterans with Tinnitus
07.08.2025 - 18:08:24 | prnewswire.co.uk
Lenire, the first and only tinnitus treatment device of its kind approved by the FDA, is now an option for 2.9 million veterans living with tinnitus through Veterans Affairs.5Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government.The General Services Administration Federal Supply Schedule 65 II Medical Equipment and Supply Contract will also make Lenire an option for patients receiving care through the Department of Defense (DoD), the Bureau of Prisons, Indian Health Services, and Public Health Services.(2022)Neuromod Devices Ltd., Lenire (CR-201) Clinician's Manual, (2023) https://www.nidcd.nih.gov/health/tinnitusUS VA Benefits Report Fiscal Year 2023: https://www.benefits.va.gov/REPORTS/abr/TENT-A3 trial data in preparation for publication: https://clinicaltrials.gov/study/NCT05227365?intr=lenire&rank=1
Photo - https://mma.prnewswire.com/media/2439154/Lenire_Neuromod_Devices.jpg
View original content:https://www.prnewswire.co.uk/news-releases/neuromods-fda-approved-lenire-device-now-a-treatment-option-for-2-9-million-us-veterans-with-tinnitus-302173371.html
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
boerse | 67930547 |

